Self Collected HPV Testing

Contents

1. The sample is not the test
2. How the sample is taken
3. Accuracy against clinician collection
4. Who is reached
5. What participation studies found
6. Approval in the United States
7. What self collection cannot do
8. Where the evidence is strongest

Self collected HPV testing changes who takes the sample, not the laboratory test or the follow up that a positive result can lead to, such as colposcopy, a procedure Candace Cooley has performed in the office throughout her career in women’s health. Two pairs of ideas are often run together in coverage of it. One is the sample and the test: a woman can collect her own sample, but the HPV test that reads it is the same one a laboratory runs on a clinician’s sample. The other is self collection and home testing, which arrived in the United States at different times and are not the same thing.

The sample is not the test

A Pap test examines the shape of cervical cells, so the sample has to come from the cervix itself. An HPV test searches instead for the genetic material of the virus. A review of self collection in screening programs explains that viral material is shed from the cervix into the vagina, so a sample from the vaginal canal is enough for HPV testing, while no body of evidence supports using a self collected sample for cytology.⁸ The Columbia University cancer center calls HPV testing extremely sensitive for high risk types and notes that it finds more high grade precancers than the Pap test alone.⁶ The older test is described in George Papanicolaou and the Pap test.

How the sample is taken

The kit is simple. Writers in STAT describe inserting a long brush with soft bristles until it stops at the cervix, twisting it several times, sealing the tip in a vial and returning it by hand or by mail.² According to the Association of Health Care Journalists, the American Cancer Society says a long cotton swab can also be used.³ In a clinic, an epidemiologist quoted by HealthDay explains, a woman is handed a kit and collects her sample in the exam room or a bathroom.⁴

Figure

Who takes the sample

	Clinician collected	Self collected
Where the sample comes from	The cervix, seen with a speculum	The vagina, with a swab or brush
Tests possible on it	HPV testing and cytology	HPV testing only
Repeat after a negative result, American Cancer Society	Five years	Three years
Groups for whom it is not a substitute	None listed	HIV, immunosuppression, prior cervical cancer, DES exposure

Accuracy against clinician collection

Accuracy depends on the laboratory method. A 2018 review in PubMed Central summarizes a 2014 meta analysis of 36 studies and 154,556 women: self samples were as sensitive as clinician samples for the most serious precancers, and a lower sensitivity for less advanced lesions appeared only with older signal based assays, not with amplification methods such as PCR.⁷ The screening program review adds that PCR based assays matched clinician samples across 17 studies, with a small loss of specificity.⁸ Single studies point the same way: the 2018 review lists agreement between the two kinds of sample of 91.4 percent in Haiti, 94.2 percent in Ghana and 96.8 percent in the Netherlands.⁷ A gynecologist interviewed by Healio puts the relative figures at roughly 0.92 to 1.01, close enough to call the methods basically the same.¹⁰

Who is reached

The case for self collection rests on who goes unscreened. Worldwide, the screening program review counts about 570,000 new cases and 311,000 deaths in 2018, most among women with no access to screening or who had not taken part in it.⁸ CNN, citing federal figures, reports that more than 11,000 cervical cancers are diagnosed in the United States each year, about 4,000 women die of the disease, and roughly half of invasive cases occur in people never screened.¹ Columbia puts screening as recommended at about 75 percent of women.⁶ Reasons given in the 2018 review include embarrassment, pain at a past exam, time away from work and distance from a clinic.⁷ The journalists’ association adds that about one in four women are not up to date, with lower rates among women living in poverty or with less schooling.³ An obstetrician quoted by Healthline says 32 percent of those behind on screening cite discomfort, and that women in rural areas face higher cervical cancer mortality.⁹

What participation studies found

Offering a kit usually raised attendance. The 2018 review reports that in Norway self sampling lifted attendance from 23.2 to 33.4 percent, and in Sweden 39 percent of long unscreened women accepted a self sampling invitation against 9 percent for a Pap smear.⁷ The screening program review adds a caution: mailed kits beat clinician invitations, 19.2 against 11.5 percent, but trials that required women to opt in did worse, 7.8 against 13.4 percent.⁸ The largest contrast in the 2018 review came from Argentina, where 86 percent of women offered self collection were tested against 20 percent of those invited to a clinic. The same review found that most women who tested positive on a self sample went on to follow up: 32 of 34 in a Norwegian study and 106 of 124 in a Chilean one.⁷

Figure

Screening attendance when self sampling was offered

• Norway, physician visit invitation23.2
• Norway, self sampling kit33.4
• Sweden, Pap smear invitation9
• Sweden, self sampling invitation39

Approval in the United States

Self collection came to the United States in steps. In May 2024, CNN reports, the Food and Drug Administration approved self collected samples for HPV testing in health care settings such as offices, urgent care and mobile clinics.¹ Columbia notes that the Preventive Services Task Force listed self collected HPV testing as a screening option in January 2025 and dates the first approved home kit to May 2025.⁶ The American Cancer Society’s December 2025 guideline, as Healthline reports, endorsed self collection from ages 25 to 65 and set a three year repeat after a negative result, shorter than the five years for clinician samples, as a margin of safety while United States data accumulate.⁹ In January 2026 federal preventive guidelines added self collection for women 30 to 65, and a gynecologic oncologist told News 12 Westchester that the home test is approved from age 30.⁵

What self collection cannot do

Because cytology cannot be run on a self sample, Healthline notes that it does not replace clinician collection for women with HIV, immunosuppression, past cervical cancer or exposure to DES before birth.⁹ A positive result still requires a visit for cytology or colposcopy, and the Healio interview warns that without a route back to care a kit only tells someone she has HPV; laboratories must also move to primary HPV screening first.¹⁰ Preferences vary: in one survey reported by the journalists’ association, over 60 percent of women preferred clinic testing.³ Invalid samples are also more common.⁸

Figure

How a self collected sample travels

1. 01
   InsertA long soft brush is inserted into the vagina until it stops at the cervix
2. 02
   TurnThe brush is twisted several times to gather enough cells
3. 03
   SealThe tip is sealed into the vial in the kit
4. 04
   ReturnThe vial goes back to an office or into the mail for laboratory HPV testing

Where the evidence is strongest

The evidence is strongest at two points: the laboratory accuracy of PCR based HPV testing on vaginal samples, and the gain in participation among women who have been missed by screening. It is thinner on long term United States results, which is why the shorter interval exists, and on women from 21 to 29, for whom Columbia notes the Pap test alone remains the method because infection at that age is frequent and the immune system typically clears it.⁶ The path from infection to disease is traced in how HPV causes cervical cancer. Whether a self collected sample suits any one woman is a question for her own clinician.